AAV in Gene Therapy Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Asklepios Biopharma, MeiraGTx, Gyroscope Therapeutics, Nanoscope Therapeutics

The AAV in Gene Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“AAV in Gene Therapy Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the AAV in Gene Therapy Market.

Some of the key takeaways from the AAV in Gene Therapy Pipeline Report:

• Companies across the globe are diligently working toward developing novel AAV in Gene Therapy treatment therapies with a considerable amount of success over the years. AAV in Gene Therapy Key players such as – Asklepios Biopharmaceutical, MeiraGTx, Gyroscope Therapeutics, Nanoscope Therapeutics, Neurophth biological tech, Lysogene, Spark Therapeutics, and others, are developing therapies for the AAV in Gene Therapy treatment

• AAV in Gene Therapy Emerging therapies such as – AAV2/8LSPhGAA, AAV CNGA3, GT 005, MCO-010, NFS-01, LYS-SAF302, SPK-9001, SPK-8011, and others are expected to have a significant impact on the AAV in Gene Therapy market in the coming years.

• In May 2026, Taysha Gene Therapies announced continued advancement of TSHA-102, an AAV-based gene therapy for Rett syndrome, with pivotal REVEAL trial enrollment and dosing progressing as planned. The company also reported FDA alignment regarding its future BLA pathway. Manufacturing validation activities for TSHA-102 were initiated to support future regulatory submissions.

• In April 2026, The FDA granted approval to Otarmeni (lunsotogene parvec-cwha), the first dual-AAV gene therapy indicated for individuals with OTOF gene-related severe-to-profound genetic hearing loss, representing a significant advancement in the development of AAV-based gene therapies.

• In April 2026, The FDA accepted the resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec), an AAV9-based gene therapy from Ultragenyx for the treatment of Sanfilippo syndrome Type A (MPS IIIA), and assigned a PDUFA target action date in September 2026.

• In March 2026, Sensorion announced positive six-month results from the Phase I/II Audiogene study of SENS-501, an AAV-based gene therapy targeting otoferlin-related congenital hearing loss, showing durable efficacy trends and a favorable safety profile. Additionally, development of GJB2-GT (SENS-601), another AAV-mediated gene therapy for genetic hearing loss, continued to advance, with regulatory filings anticipated in 2026.

AAV in Gene Therapy Overview

AAV stands for adeno-associated virus, a small, non-pathogenic virus that has gained significant attention in the field of gene therapy. AAV has become a popular vector for delivering therapeutic genes into target cells for the treatment of various genetic disorders and other diseases.

Get a Free Sample PDF Report to know more about AAV in Gene Therapy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight

Route of Administration

AAV in Gene Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intracerebral

• Intracerebroventricular

• Intracisternal

• Intramuscular

• Intraocular

• Intrapancreatic

• Intrastriatal

• Intrathecal

• Intravenous

• Intravitreous

• Introvitinreous

• Oral

• Parenteral

• Retinal

• Intra-arterial

• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

AAV in Gene Therapy Pipeline Therapeutics Assessment

• AAV in Gene Therapy Assessment by Product Type

• AAV in Gene Therapy By Stage and Product Type

• AAV in Gene Therapy Assessment by Route of Administration

• AAV in Gene Therapy By Stage and Route of Administration

• AAV in Gene Therapy Assessment by Molecule Type

• AAV in Gene Therapy by Stage and Molecule Type

DelveInsight’s AAV in Gene Therapy Report covers around 250+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further AAV in Gene Therapy product details are provided in the report. Download the AAV in Gene Therapy pipeline report to learn more about the emerging AAV in Gene Therapy therapies

Emerging AAV in Gene Therapy Drugs Under Different Phases of Clinical Development Include:

• AAV2/8LSPhGAA: Asklepios Biopharmaceutical

• AAV CNGA3: MeiraGTx

• GT 005: Gyroscope Therapeutics

• MCO-010: Nanoscope TherapeuticsXX

• NFS-01: Neurophth biological tech

• LYS-SAF302: Lysogene

• SPK-9001: Spark Therapeutics

• SPK-8011: Spark Therapeutics

AAV in Gene Therapy Pipeline Analysis:

The AAV in Gene Therapy pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of AAV in Gene Therapy with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for AAV in Gene Therapy Treatment.

• AAV in Gene Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• AAV in Gene Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the AAV in Gene Therapy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about AAV in Gene Therapy drugs and therapies

AAV in Gene Therapy Pipeline Market Drivers

• Growing number of gene therapy approvals and clinical successes is increasing confidence in adeno-associated virus (AAV) vectors as effective delivery platforms.

• Rising prevalence of rare genetic disorders and inherited diseases is driving demand for one-time, potentially curative gene therapies.

• Advancements in AAV vector engineering are improving tissue targeting, transgene expression, and therapeutic efficacy.

• Increasing investments from biotechnology and pharmaceutical companies are accelerating AAV-based gene therapy research and development.

• Supportive regulatory pathways and orphan drug incentives are encouraging innovation and faster development of AAV-mediated therapies.

AAV in Gene Therapy Pipeline Market Barriers

• High development and manufacturing costs remain a significant challenge, limiting accessibility and commercial scalability.

• Limited packaging capacity of AAV vectors restricts the delivery of larger therapeutic genes.

• Pre-existing immunity to AAV serotypes in patients can reduce treatment effectiveness and complicate patient selection.

• Concerns regarding long-term safety and durability of gene expression continue to require extensive clinical evaluation.

• Complex manufacturing processes and supply chain constraints can delay clinical development and commercialization.

Scope of AAV in Gene Therapy Pipeline Drug Insight

• Coverage: Global

• Key AAV in Gene Therapy Companies: Asklepios Biopharmaceutical, MeiraGTx, Gyroscope Therapeutics, Nanoscope Therapeutics, Neurophth biological tech, Lysogene, Spark Therapeutics, and others

• Key AAV in Gene Therapy Therapies: AAV2/8LSPhGAA, AAV CNGA3, GT 005, MCO-010, NFS-01, LYS-SAF302, SPK-9001, SPK-8011, and others

• AAV in Gene Therapy Therapeutic Assessment: AAV in Gene Therapy current marketed and AAV in Gene Therapy emerging therapies

• AAV in Gene Therapy Market Dynamics: AAV in Gene Therapy market drivers and AAV in Gene Therapy market barriers

Request for Sample PDF Report for AAV in Gene Therapy Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gauarv Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/